FindTrial
Sign In

Eicosapentaenoic Acid Supplementation Modulates Osteopontin Levels in Hemodialysis Patients

Evaluation of the potential use of EPA to prevent osteoporosis in renal dialysis patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107328
Enrollment
Unknown
Registered
2025-08-08
Start date
2024-02-28
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Experimental group:Taking fish oil
Control group:Placebo

Sponsors

Hungkuang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age 40 to 70 years old; 2. Chronic kidney disease patients receiving hemodialysis.

Exclusion criteria

Exclusion criteria: 1. Acute kidney injury occurred during the case; 2. The patient had received a kidney transplant before the case was admitted; 3. Patients with malignant tumors; 4. The medical records are incomplete or the information is insufficient, making it impossible to obtain complete case information; 5. People who are allergic to fish; 6. Patients with poor coagulation function (blood disease or liver cirrhosis) or patients taking anticoagulants.

Design outcomes

Primary

MeasureTime frame
OPN;—

Secondary

MeasureTime frame
bone mineral desity ;—

Countries

China

Contacts

Public ContactCHIANG TSAY -I

Hungkuang University

tsai.yi00@msa.hinet.net+886 916 990 431

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026